Clinical trial
A Phase 3, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% Applied to a Field of Approximately 100 cm2 on the Face or Balding Scalp in Adult Patients With Actinic Keratosis
NCT05279131 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% Applied to a Field of Approximately 100 cm2 on the Face or Balding Scalp in Adult Patients With Actinic Keratosis
- Lead sponsor
- Almirall, S.A.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 28, 2022
- Completion date
- December 28, 2022
- Enrollment
- 105 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.